{"id":20802,"date":"2016-01-16T00:15:18","date_gmt":"2016-01-16T08:15:18","guid":{"rendered":"http:\/\/lifeboat.com\/blog\/2016\/01\/intellia-therapeutics-launches-new-division-to-accelerate-ex-vivo-programs-with-crisprcas9"},"modified":"2017-04-24T23:00:48","modified_gmt":"2017-04-25T06:00:48","slug":"intellia-therapeutics-launches-new-division-to-accelerate-ex-vivo-programs-with-crisprcas9","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2016\/01\/intellia-therapeutics-launches-new-division-to-accelerate-ex-vivo-programs-with-crisprcas9","title":{"rendered":"Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR\/Cas9"},"content":{"rendered":"<p><a class=\\'blog-photo\\' href=\"https:\/\/lifeboat.com\/blog.images\/intellia-therapeutics-launches-new-division-to-accelerate-ex-vivo-programs-with-crisprcas9.jpg\"><\/a><\/p>\n<p>Excellent news; Intellia to continue their focus of leveraging the CRISPR\/Cas9 across a variety of immune cells, such as natural killer cells and T-cells. From my own experiences with T-cells and other blood disorders; this is a big deal and one that I personally excited to see what potential cures and improvements come about.<\/p>\n<hr>\n<p>CAMBRIDGE, Mass.\u2013(<a rel=\"nofollow\" itemprop=\"url\" href=\"http:\/\/www.businesswire.com\/\">BUSINESS WIRE<\/a>)\u2013Intellia Therapeutics, a leading gene-editing company, has launched a new division, eXtellia Therapeutics, with the intent of focusing resources and research on <i>ex vivo<\/i> applications of the novel technology, CRISPR\/Cas9. As <i>in vivo<\/i> and <i>ex vivo<\/i> programs require different competencies in research, manufacturing and commercialization, eXtellia Therapeutics is being launched to accelerate Intellia\u2019s efforts in areas of significant unmet medical need \u2013 immuno-oncology, autoimmune and inflammatory diseases \u2013 using an <i>ex vivo<\/i> approach. Intellia will continue its <i>in vivo<\/i> programs and strategy through a dedicated scientific team.<\/p>\n<blockquote><\/blockquote>\n<p>\u201cWe are excited to announce the establishment of eXtellia, increasing our footprint in <i>ex vivo<\/i> gene editing for oncology and autoimmune diseases,\u201d said Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics. \u201ceXtellia enables us to bring together the required capabilities needed to take the CRISPR\/Cas9 technology beyond Intellia\u2019s emerging <i>in vivo<\/i>, HSC and CAR-T efforts. We believe eXtellia further positions us to maximize the CRISPR\/ Cas9 opportunity to address severe unmet medical needs for patients.\u201d<\/p>\n<p><a href=\"http:\/\/www.businesswire.com\/news\/home\/20160112005470\/en\/\" target=\"_blank\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Excellent news; Intellia to continue their focus of leveraging the CRISPR\/Cas9 across a variety of immune cells, such as natural killer cells and T-cells. From my own experiences with T-cells and other blood disorders; this is a big deal and one that I personally excited to see what potential cures and improvements come about. CAMBRIDGE, [\u2026]<\/p>\n","protected":false},"author":395,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,43,412],"tags":[],"class_list":["post-20802","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-business","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/20802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/395"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=20802"}],"version-history":[{"count":2,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/20802\/revisions"}],"predecessor-version":[{"id":51162,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/20802\/revisions\/51162"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=20802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=20802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=20802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}